Exagen appoints Tina S. Nova, Ph.D. as Executive Chair, effective Jan 19, 2023

EXAGEN INC.

Dr. Nova replaces Brian Birk, who remains on the Board.
Nova is President of Veracyte's U.S. CLIA business; former CEO of Decipher Biosciences.
Nova co-founded Genoptix (sold to Novartis for $470M) and held leadership at Illumina.
Company says her experience will help expand its position in autoimmune testing.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

EXAGEN INC.: Adopted amendment to bylaws to allow Board to appoint an executive chairperson of the Board, who shall also be chairperson of the Board and an officer of the Company, and to empower the executive chairperson to appoint other officers and agents as the business may require (effective 2023-01-19).

Change: bylaw amendment
Effective: 2023-01-19

Exact text from the filing

On January 19, 2023, the board of directors (the “Board”) of Exagen Inc. (the “Company”) adopted an amendment (the “Bylaws Amendment”) to the amended and restated bylaws of the Company to provide that the Board may appoint from its members an executive chairperson of the Board and that the executive chairperson, if any, shall also be the chairperson of the Board and an officer of the Company.

View on SEC.gov

Browse all governance changes →

EXAGEN INC. filing history →

Source: SEC EDGAR

accession 0001274737-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.